Humacyte lawsuite is questionableAs a scientist, I have been in medical device development and manufacturing. Every company faces ups and downs in manufacturing medical devices. FDA regularly visits those companies for audits. As an investor, I hired and a FDA compliance expert about two weeks ago to analyze the FDA findings and decide whether I shall sell my shares. According to the expert, the FDA findings were not significant and the issues could have been fixed easily. I humbly think that Humacyte management did not own to it shareholders for disclosing such non-significant and easily fixable nuances. As such, I have been keeping my shares in the stock. My two cents on this topic.
Humacyte
$HUMA - New Swing Long Trade Opportunity?NASDAQ:HUMA
Hello everyone! I'm sharing both the weekly and daily charts with you. On the weekly chart (you can see below), the price tested the 100 EMA and rebounded. On the daily chart, after reaching the 30 RSI level, the price bounced back, stayed above the 100 EMA, and the UT Bot Indicator signalled a Buy. It appears the asset price has completed its correction.
I’m considering a swing-long trade with a Stop Loss set at $4.60. This could be a promising swing opportunity. A new higher high from this point indicates a potential return of nearly 90%, while reaching $8 would offer a return of about 50% profit. If the price hits my stop loss, it would result in a 13% loss. With risk-to-reward ratios of 7 and 4, this represents an excellent trading opportunity.
Additionally, the current market sentiment and volume trends support a bullish outlook. The asset has shown strong support at the 100 EMA, reinforcing the potential for upward movement. It's important to keep an eye on upcoming economic data releases and market events, as they could influence price action. This setup aligns well with my trading strategy, focusing on high-probability trades with favourable risk-to-reward ratios. Let's watch for a sustained breakout to maximize gains.
Weekly Chart:
HUMA Humacyte Options Ahead of EarningsIf you haven't sold HUMA before the previous earnings:
Then analyzing the options chain and the chart patterns of HUMA Humacyte prior to the earnings report this week,
I would consider purchasing the 5usd strike price Calls with
an expiration date of 2024-9-20,
for a premium of approximately $1.22.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
HUMA Humacyte Options Ahead of EarningsAnalyzing the options chain and the chart patterns of HUMA Humacyte prior to the earnings report this week,
I would consider purchasing the 5usd strike price in the money Puts with
an expiration date of 2024-4-19,
for a premium of approximately $1.55.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.